Subject(s)
Humans , Male , Middle Aged , Thrombotic Microangiopathies , Hypertension, Pulmonary , Prognosis , ThrombosisSubject(s)
Carcinoma, Transitional Cell , Hypertension, Pulmonary , Lung Neoplasms , Neoplastic Cells, Circulating , Thrombotic Microangiopathies , Urinary Bladder Neoplasms , Humans , Carcinoma, Transitional Cell/complications , Urinary Bladder Neoplasms/complications , Urinary Bladder Neoplasms/pathology , Lung/pathology , Hypertension, Pulmonary/etiology , Thrombotic Microangiopathies/etiology , Thrombotic Microangiopathies/pathology , Neoplastic Cells, Circulating/pathology , Lung Neoplasms/complications , Lung Neoplasms/pathologySubject(s)
Humans , Female , Middle Aged , Acute Disease , Coronavirus , Pancreatitis , Diabetes Mellitus , Hypertension , Overweight , HyperlipidemiasSubject(s)
COVID-19 , Pancreatitis, Acute Hemorrhagic , Acute Disease , COVID-19/complications , Humans , SARS-CoV-2ABSTRACT
Introducción: En el contexto de la pandemia mundial por COVID-19, las distintas manifestaciones clínicas de esta infección suponen un reto para los profesionales sanitarios. La afectación respiratoria, síntoma principal de la infección por SARS-CoV-2, hace que otras manifestaciones, como las neurológicas, pasen a un segundo plano, con el consecuente retraso en el diagnóstico y tratamiento.Material y métodosTodo paciente COVID-19 que ha ingresado con sintomatología neurológica o diagnosticado de encefalitis desde marzo de 2020 en un hospital de tercer nivel en Zaragoza, España.ResultadosDos pacientes con infección COVID-19 confirmada por reacción en cadena de la polimerasa (PCR) nasofaríngea y cuyo cuadro clínico consistía en alteraciones neurológicas compatibles con encefalitis. La microbiología del líquido cefalorraquídeo (LCR) fue negativa para bacterias y virus, incluido el SARS-CoV-2 pero, ante la sospecha clínica de encefalitis por este último, se instauró tratamiento antiviral, con inmunoglobulinas y plasmaféresis de forma precoz. A pesar de ello la evolución no fue satisfactoria.ConclusionesLa encefalitis por COVID-19 es una entidad clínica descrita recientemente, cuya fisiopatología aún se desconoce y no se dispone, hasta la fecha, de un tratamiento con evidencia clínica. (AU)
Introduction: In the context of the global COVID-19 pandemic, the different clinical manifestations of this infection pose a challenge for healthcare professionals. Respiratory involvement, the main symptom of SARS-CoV-2 infection, means that other manifestations, such as neurological, take a back seat, with the consequent delay in diagnosis and treatment.Material and methodsAll COVID-19 patients admitted with neurological symptoms or diagnosed with encephalitis since March 2020 in a tertiary hospital in Zaragoza, Spain.ResultsTwo patients with COVID-19 infection confirmed by nasopharyngeal PCR and whose clinical picture consisted of neurological alterations compatible with encephalitis. Cerebrospinal fluid (CSF) microbiology was negative for bacteria and viruses, including SARS-CoV-2 but, given the clinical suspicion of encephalitis due to the latter, antiviral treatment with immunoglobulins and plasmapheresis was started early. Despite this, the evolution was not satisfactory.ConclusionsCOVID-19 encephalitis is a recently described clinical entity, whose pathophysiology is still unknown and no treatment with clinical evidence is available to date. (AU)
Subject(s)
Humans , Male , Middle Aged , Aged , Severe acute respiratory syndrome-related coronavirus , Coronavirus Infections/complications , Encephalitis/diagnosis , Encephalitis/virology , Nervous System Diseases/diagnosis , Nervous System Diseases/virology , Pandemics , SpainABSTRACT
INTRODUCTION: In the context of the global COVID-19 pandemic, the different clinical manifestations of this infection pose a challenge for healthcare professionals. Respiratory involvement, the main symptom of SARS-CoV-2 infection, means that other manifestations, such as neurological, take a back seat, with the consequent delay in diagnosis and treatment. MATERIAL AND METHODS: All COVID-19 patients admitted with neurological symptoms or diagnosed with encephalitis since March 2020 in a tertiary hospital in Zaragoza, Spain. RESULTS: Two patients with COVID-19 infection confirmed by nasopharyngeal PCR and whose clinical picture consisted of neurological alterations compatible with encephalitis. Cerebrospinal fluid (CSF) microbiology was negative for bacteria and viruses, including SARS-CoV-2 but, given the clinical suspicion of encephalitis due to the latter, antiviral treatment with immunoglobulins and plasmapheresis was started early. Despite this, the evolution was not satisfactory. CONCLUSIONS: COVID-19 encephalitis is a recently described clinical entity, whose pathophysiology is still unknown and no treatment with clinical evidence is available to date.
INTRODUCCIÓN: En el contexto de la pandemia mundial por COVID-19, las distintas manifestaciones clínicas de esta infección suponen un reto para los profesionales sanitarios. La afectación respiratoria, síntoma principal de la infección por SARS-CoV-2, hace que otras manifestaciones, como las neurológicas, pasen a un segundo plano, con el consecuente retraso en el diagnóstico y tratamiento. MATERIAL Y MÉTODOS: Todo paciente COVID-19 que ha ingresado con sintomatología neurológica o diagnosticado de encefalitis desde Marzo de 2020 en un hospital de tercer nivel en Zaragoza, España. RESULTADOS: Dos pacientes con infección COVID-19 confirmada por PCR nasofaríngea y cuyo cuadro clínico consistía en alteraciones neurológicas compatibles con encefalitis. La microbiología del líquido cefalorraquídeo (LCR) fue negativa para bacterias y virus, incluido el SARS-CoV-2 pero, ante la sospecha clínica de encefalitis por este último, se instauró tratamiento antiviral, con inmunoglobulinas y plasmaféresis de forma precoz. A pesar de ello la evolución no fue satisfactoria. CONCLUSIONES: La encefalitis por COVID-19 es una entidad clínica descrita recientemente, cuya fisiopatología aún se desconoce y no se dispone, hasta la fecha, de un tratamiento con evidencia clínica.
ABSTRACT
INTRODUCTION: In the context of the global COVID-19 pandemic, the different clinical manifestations of this infection pose a challenge for healthcare professionals. Respiratory involvement, the main symptom of SARS-CoV-2 infection, means that other manifestations, such as neurological, take a back seat, with the consequent delay in diagnosis and treatment. MATERIAL AND METHODS: All COVID-19 patients admitted with neurological symptoms or diagnosed with encephalitis since March 2020 in a tertiary hospital in Zaragoza, Spain. RESULTS: Two patients with COVID-19 infection confirmed by nasopharyngeal PCR and whose clinical picture consisted of neurological alterations compatible with encephalitis. Cerebrospinal fluid (CSF) microbiology was negative for bacteria and viruses, including SARS-CoV-2 but, given the clinical suspicion of encephalitis due to the latter, antiviral treatment with immunoglobulins and plasmapheresis was started early. Despite this, the evolution was not satisfactory. CONCLUSIONS: COVID-19 encephalitis is a recently described clinical entity, whose pathophysiology is still unknown and no treatment with clinical evidence is available to date.
